DESMOPRESSIN ACETATE (desmopressin acetate) by Aurobindo Pharma is acetate's primary pharmacodynamic action involves its binding to vasopressin 2 (v2) receptors. Approved for nephrogenic diabetes insipidus, central diabetes insipidus. First approved in 2024.
acetate's primary pharmacodynamic action involves its binding to vasopressin 2 (V2) receptors. V2 receptors are primarily located in the distal convoluted tubule and collecting ducts of the nephron in the kidneys. These receptors play a crucial role in regulating water reabsorption and urine…
Worked on DESMOPRESSIN ACETATE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Desmopressin Acetate 0.2 mg Tablets, Fasting
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo